Innoviz Technologies (INVZ) Chief R&D Officer details shares, options and RSUs

Rhea-AI Filing Summary

Innoviz Technologies Ltd. Chief R&D Officer Avishay Ben Moscovici filed an initial ownership report showing his equity position in the company. He directly holds 330,665 ordinary shares, along with multiple share option grants over ordinary shares with exercise prices ranging from $0.5695 to $11.50 and expirations between 2027 and 2032.

The filing also notes 172,296 ordinary shares issuable upon vesting of restricted share units (RSUs), granted between 2022 and 2025, with quarterly vesting schedules running through 2029, subject to his continued service. Each RSU represents a contingent right to receive one ordinary share.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Moscovici Avishay Ben

(Last) (First) (Middle)

C/O INNOVIZ TECHNOLOGIES LTD.

5 URI ARIAV STREET, BUILDING C

(Street)

ROSH HA'AIN 4809202

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Innoviz Technologies Ltd. [ INVZ ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	330,665(1)(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option(3)	(3)	12/31/2027	Ordinary Shares	65,322	$0.5695	D
Share Option(3)	(3)	02/10/2030	Ordinary Shares	31,607	$1.139	D
Share Option(3)	(3)	05/12/2028	Ordinary Shares	39,504	$9.92	D
Share Option(3)	(3)	05/12/2028	Ordinary Shares	60,667	$11.5	D
Share Option(4)	(4)	08/09/2029	Ordinary Shares	24,064	$5.23	D
Share Option(5)	(5)	08/01/2030	Ordinary Shares	30,144	$4.03	D
Share Option(6)	(6)	08/20/2031	Ordinary Shares	48,480	$0.75	D
Share Option(7)	(7)	08/05/2032	Ordinary Shares	53,120	$1.61	D

Explanation of Responses:

1. Includes 172,296 ordinary shares issuable upon vesting of restricted share units ("RSUs"); of which (a) 4,010 RSUs granted August 9, 2022, vesting in equal quarterly installments through 2026; (b) 12,810 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 14,636 RSUs granted February 27, 2024, with 2,684 vesting quarterly through 2027 and 11,952 vesting quarterly through 2028; (d) 28,280 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 14,928 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 49,584 RSUs granted August 5, 2025, one-fourth vesting on August 5, 2026, remainder vesting quarterly through 2029; and (g) 48,048 RSUs granted November 11, 2025, one-fourth vesting on November 11, 2026, remainder vesting quarterly through 2029. Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share.

2. No exercise price is applicable.

3. Immediately exercisable.

4. Share options granted on August 9, 2022. Includes 21,056 vested options, and 3,008 unvested options, which shall vest in equal quarterly installments through 2026, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.

5. Share options granted on August 1, 2023. Includes 18,840 vested options, and 11,304 unvested options, which shall vest in equal quarterly installments through 2027, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.

6. Share options granted on August 20, 2024. Includes 18,180 vested options, and 30,300 unvested options, which shall vest in equal quarterly installments through 2028, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.

7. Share options granted on August 5, 2025. Includes no vested options, and 53,120 unvested options, with one-fourth of the options vesting on August 5, 2026, and the remaining shall vest in equal quarterly installments through 2029, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.

Remarks:

[Exhibit 24 - Power of Attorney.]

	/s/ Dafna Raz - Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Innoviz Technologies (INVZ) Chief R&D Officer report on this Form 3?

The Chief R&D Officer reports his initial equity holdings in Innoviz, including 330,665 ordinary shares held directly and several share option grants over ordinary shares, plus a significant block of RSUs that may convert into shares over time.

How many Innoviz (INVZ) ordinary shares does the officer currently hold directly?

The officer holds 330,665 ordinary shares directly. This figure represents his existing common equity stake, separate from any options or restricted share units that may vest or be exercised into additional ordinary shares in the future.

What stock options are disclosed for the Innoviz (INVZ) Chief R&D Officer?

The filing lists multiple share option grants over ordinary shares with exercise prices from $0.5695 to $11.50 and expiration dates between 2027 and 2032, reflecting a mix of vested and unvested options tied to continued service.

How many RSUs are reported by the Innoviz (INVZ) officer and how do they vest?

The officer reports 172,296 ordinary shares issuable upon RSU vesting. These RSUs were granted from 2022 to 2025 and generally vest in equal quarterly installments through 2029, contingent on the officer remaining a service provider.

Does this Innoviz (INVZ) Form 3 show insider buying or selling activity?

The Form 3 does not show buying or selling activity. It is an initial ownership report that outlines existing holdings of ordinary shares, share options and RSUs, rather than recording new market transactions in Innoviz stock.

What is the significance of the expiration dates on Innoviz (INVZ) share options?

Each option grant has a specified expiration date between 2027 and 2032. The officer must exercise options before their respective expiration dates if he wishes to convert them into ordinary shares, subject to vesting and any plan conditions.